Baxter International Inc. stock underperforms Thursday when compared to competitors
Baxter International Inc. closed 29.99% short of its 52-week high of $44.01, which the company reached on March 8th.
Baxter announces CEO’s immediate retirement, days after $3.7B sale of kidney care business
Deerfield-based Baxter International announced Monday that its CEO and board Chair José Almeida is retiring, effective ...
Baxter International Inc. (NYSE:BAX) Given Average Rating of “Hold” by Analysts
Baxter International Inc. (NYSE:BAX – Get Free Report) has been assigned an average recommendation of “Hold” from the ten brokerages that are covering the stock, MarketBeat.com reports. One equities ...
Baxter International: A Possible Value Trap
Despite strong revenue growth, Baxter struggles with profitability and high long-term debt. Click here to read why BAX stock ...
Baxter Kidney Care is Now Vantive, A New Standalone Vital Organ Therapy Company
Vantive builds on a 70-year legacy of kidney care leadership and innovation, with a singular focus on empowering patients and ...
Baxter International Inc. CEO Transition and Financial Update
Baxter International Inc. (NYSE: BAX) has recently announced significant changes to its executive leadership and provided an update on its financial outlook through an 8-K filing with the Securities ...
Baxter Kidney Care becomes Vantive following acquisition by Carlyle funds
Vantive, formerly the Baxter Kidney Care segment, launched as a new standalone vital organ therapy company following the completion of its ...
Baxter International Weighing Potential Tariff Impact
Baxter International said it weighing the potential impact of the Trump administration's planned tariffs on the medical-products maker's guidance.